KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accumulated Expenses (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Accumulated Expenses for 11 consecutive years, with $13.0 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 29.7% to $13.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, down 29.7% year-over-year, with the annual reading at $13.0 million for FY2025, 29.7% down from the prior year.
  • Accumulated Expenses hit $13.0 million in Q4 2025 for CRISPR Therapeutics AG, up from $10.2 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $91.0 million in Q4 2021 to a low of $6.1 million in Q1 2025.
  • Historically, Accumulated Expenses has averaged $38.0 million across 5 years, with a median of $17.9 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: surged 528.03% in 2022 and later tumbled 88.5% in 2023.
  • Year by year, Accumulated Expenses stood at $91.0 million in 2021, then decreased by 14.64% to $77.7 million in 2022, then crashed by 77.67% to $17.3 million in 2023, then increased by 6.32% to $18.4 million in 2024, then dropped by 29.7% to $13.0 million in 2025.
  • Business Quant data shows Accumulated Expenses for CRSP at $13.0 million in Q4 2025, $10.2 million in Q3 2025, and $73.7 million in Q2 2025.